Next Phase Newsletter

By Karen Deyo, Director of Investor Research, Israel BD, LSN

Partnering for RESI Partnering Week, taking place September 13-17, launches Monday, giving companies a chance to connect with investors. The LSN Partnering Platform offers startups an unprecedented opportunity to search for and identify investors that are a fit for them based on sector, stage of development and other helpful criteria. Successful partnering takes a lot of work, and the companies that book the most meetings send, on average, over 100 meeting requests to relevant investors, followed by frequent follow-ups. We will be offering free partnering tutorials for registered attendees in the weeks before the conference takes place. Take a look at the registered investors below, and make sure to register now before partnering launches!

Confirmed RESI Partnering Week Investors

A private life science investment firm with a presence in USA, Canada, and Western Europe, looks to make investments into privately held companies and while the firm can be flexible in terms of allocation size, most investments fall in the $.5-$3million range. The firm is open to investing in companies located around the globe.

The firm is currently looking for therapeutics companies across all indication areas with particular attention to metabolic diseases (including type II diabetes), immunoncology, aging, and infectious diseases. The firm is interested in pre-clinical stage companies that have a lead asset established as well as companies in early clinical trials. The firm is open to all molecule types that meet this criteria. The firm is generally not interested in next generation cytotoxic chemotherapies, therapies for Alzheimer’s Disease, or therapies for cardiovascular indications.

The firm acts as hands-on investors who contribute substantially to the operation of their portfolio companies, often supplementing management with a network of drug developers and specialists in regulatory affairs, clinical affairs, manufacturing, and other subspecialties.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A family office founded over 30 years ago has recently been restarted, and has recently transitioned to have a stronger healthcare focus after coming out of dormancy and is seeking to make equity investments in the $200K – $2M USD range. The firm is a multi-stage longer term oriented investor interested in new and more seasoned emerging growth companies addressing a broad range of Healthcare and Medical products and services opportunities. The firm invests in companies based in North America and Europe and is actively seeking new investment opportunities.

The firm is interested in Medtech and Healthcare IT projects that are transformative and disruptive within their fields. The firm is not interested in therapeutics, vaccines, molecules, or any healthcare projects with undefined regulatory approval cycles. Otherwise, the firm is rather opportunistic within the Medtech and Healthcare IT sectors.

When investing, the firm seeks a board seat and prefers to get involved with the management team. As a result, the firm prefers a management team that is willing to work with them together as partners.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A cross-border venture capital firm headquartered in Asia with USA offices, with a recently launched incubator business, typically makes an initial investment ranging from under $1 million to $3-6 million dependent on the company’s stage of development. The firm can allocate up to $16 million over the lifetime of a company. The firm invests in early-stage therapeutic companies worldwide.

The firm only invests in therapeutics, and are primarily focused on companies with preclinical or clinical assets. Within therapeutics, all modalities are of interest. The firm may invest up to 18 months prior to IND, however require that a company has a lead asset that has been characterized. The firm will consider opportunities in any indication area.

The firm invests in teams with experienced, highly motivated teams with a strong background in either life science research or industry. The firm only invests in companies with technology that has the potential to be first in class.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A firm that operates a large hospital network across Asia and the Middle East has an innovation office that acts as a corporate VC arm, which has committed capital of $80 million to invest in the digital health space. The firm typically invests $5-10 million per opportunity, and will invest in companies worldwide that are interested in expanding into Asia.

The firm only invests in the digital health space. The firm is interested in many areas of digital health, diagnostics, and tech-enabled healthcare services, including wellness, digital therapeutics, AI, healthcare data, remote monitoring, chronic disease management, etc.  The firm does not invest in biopharma or medtech.

The firm will invest globally, and is focused on startups that are interested in expanding into Asia.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.